IFN-α subtypes: distinct biological activities in anti-viral therapy.
During most viral infections, the immediate host response is characterized by an induction of type I IFN. These cytokines have various biological activities, including anti-viral, anti-proliferative and immunomodulatory effects. After induction, they bind to their IFN-α/β receptor, which leads to downstream signalling resulting in the expression of numerous different IFN-stimulated genes. These genes encode anti-viral proteins that directly inhibit viral replication as well as modulate immune function. Thus, the induction of type I IFN is a very powerful tool for the host to fight virus infections. Many viruses evade this response by various strategies like the direct suppression of IFN induction or inhibition of the IFN signalling pathway. Therefore, the therapeutic application of exogenous type I IFN or molecules that induce strong IFN responses should be of great potential for future immunotherapies against viral infections. Type I IFN is currently used as a treatment in chronic hepatitis B and C virus infection, but as yet is not widely utilized for other viral infections. One reason for this restricted clinical use is that type I IFN belongs to a multigene family that includes 13 different IFN-α subtypes and IFN-β, whose individual anti-viral and immunomodulatory properties have so far not been investigated in detail to improve IFN therapy against viral infections in humans. In this review, we summarize the recent achievements in defining the distinct biological functions of type I IFN subtypes in cell culture and in animal models of viral infection as well as their clinical usage in chronic hepatitis virus infections.
Department of Virology, University Hospital Essen, Essen, Germany. kathrin.gibbert@uni-due.de
K
K
Gibbert
J F
JF
Schlaak
D
D
Yang
U
U
Dittmer
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use*; D021122:Protein Subunits / Q000494:pharmacology / Q000627:therapeutic use*; D014777:Virus Diseases / Q000188:drug therapy*
D000998:Antiviral Agents; D007370:Interferon Type I; D021122:Protein Subunits